From the "Sublime -- to Ridiculous" Dept.: Why It's Always a Good Idea to Proof Press Releases. . . .

Seeking Alpha, a great resource site, has dutifully lifted the first version of Schering-Plough's asenapine press release, of last afternoon, to source this (below). The problem is that Schering-Plough's original press release used a would-be "New-Joisey"-homonym in place of the intended word -- "use" (erroneously substituting "youth", instead).

With the error, the sentence is wholly-unintelligible. There was no vote for approvability, of that sort, yesterday. So, I guess it is usually wise to really proof corporate press releases -- especially on one of Schering-Plough's "Five Star" candidates, now pending-action, at FDA:

. . . .in favor of Saphris (asenapine) sublingual tablets as effective and safe for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and in favor of youth USE(!) in acute treatment of schizophrenia in adults. . . .

That was the Seeing Alpha quote, as corrected, here. It seems "the lights are all on", in Kenilworth, but "no one's home"(!). I actually thought the pronunciation of "youth", as a New Joisey near-homonym for "use" was more of a "Sout-Philly" thing. As I say -- trivial, but telling, nonetheless.